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Complexes between the urokmase-type plasminogen activator (uPA) and its type-2 inhibttor (PAI-2) are bound by a cell-surface receptor for uPA 
and rapidly cleaved mto two fragments of 70 and 22 kDa. The 70-kDa fragment contains the active site of uPA and PAI-2, while the 22-kDa species 
was identified as the ammo terminal fragment of uPA, that binds specifically to the receptor. When the expertment is performed at 4°C. both 
fragments remain bound to the cell surface and can be eluted by acid treatment. We therefore postulate that after the binding of the uPA-PAI- 
complex, a new binding site for the 70-kDa species becomes available. This additional binding favours the cleavage of the complex into the 70- 
and 22-kDa fragments; the 70-kDa species IS endocytosed or released, while the 22-kDa fragment remains on the cell surface to prevent the binding 
of intact uPA. 
Urokinase; Urokmase receptor: uPA; uPA-R; PAI- 
1, INTRODUCTION 
The proteolytic degradation of the elements of the 
extracellular matrix is an important step in many phys- 
iological processes that involve cellular migration and 
tissue remodelling. Proteolytic degradation, moreover, 
seems to play an important role also in such pathologi- 
cal processes as metastasis and inflammation. Plasmin 
is a broad-spectrum proteolytic enzyme that degrades 
many components of the extracellular matrix, directly 
or by activating latent collagenases. It originates from 
a zymogen present in extracellular fluids, plasminogen, 
by a single proteolytic cleavage catalyzed by two plas- 
minogen activators (PA): the urokinase-type (UPA) and 
the tissue-type (tPA). The latter is involved mainly in 
fibrinolysis, while UPA is considered the key enzyme in 
the above-mentioned processes [1,2]. The activity of 
both PAS is regulated by two specific inhibitors, PAI- 
and PAI-2, and their localization is controlled by spe- 
cific cellular receptors [2,3]. 
UPA is synthesized in several cells as pre-pro-uPA; the 
removal of the signal peptide gives the secreted form, 
pro-uPA, which is almost inactive. Pro-uPA is a single- 
chain glycosylated polypeptide; a single cleavage after 
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Lys-158 yields the active form consisting of two chains, 
A and B, linked by a disulfide bridge [l-3]. 
Many cell types of different species express on their 
surface a UPA receptor (uPAR) [4--81: the receptor con- 
sists of a single glycosylated polypeptide chain of about 
55 kDa, maintained on the cell surface by a GPI anchor 
[9,10]. uPAR binds with high affinity the active form of 
the enzyme [4], its zymogen, pro-uPA [l 11, the enzyme 
inactivated by diisopropylfluorophosphate (DFP) and, 
finally, also UPA complexed with one of its inhibitors, 
albeit with a slightly lower affinity [12,13]. Binding to 
the receptor involves only the amino terminal portion 
of the enzyme and does not affect its catalytic activity. 
Therefore, the A chain and its amino terminal fragment 
(ATF) binds uPAR [4.5,14], while the B chain and the 
so-called ‘low-molecular-weight uPA’ uPA (residues 
136-l 58, A chain; and 1599411, B chain) that contain 
the active site of the enzyme, do not [12,13]. 
PAI- was first identified by Kawano in human pla- 
centa [15]; it differs from the other inhibitor, PAI-1, in 
terms of secretion, localization and stability [2,3], and 
it inhibits UPA by forming a covalent bond with the 
active site of the B chain, both in solution and with the 
enzyme bound to its cellular receptor [12,13]. 
If the UPA-PAI- complex (92 kDa) is bound to the 
uPAR on the surface of a monocyte-like cell line (THP- 
I), it originates a degradation product of 70 kDa [13]. 
At 37”C, both the native complex and the degradation 
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product disappear. These observations suggested that 
the complex undergoes a partial degradation involving 
mainly the inhibitor. followed, at 37°C. by endocytosis 
and total degradation. In this way the uPA-PAI- com- 
plex would be rapidly removed from the cell surface. 
To analyze the steps and the products of the degrada- 
tion process, we have performed binding experiments 
on the cell line THP-1, at 4°C. The results show that the 
degradation process causes the cleavage of the uPA- 
PAI- complex into two parts, both bound to the cell 
surface: the A chain of UPA and the B chain still com- 
plexed with the inhibitor. We propose a model whereby 
PAI- regulates the cell surface-associated proteolytic 
activity of UPA: a conformational modification of the 
UPA receptor. followed by the exposure of a new bind- 
ing site. probably for PAI- and the cleavage of the 
uPA_PAI- complex. 
2. MATERIALS AND METHODS 
2 1. Cl811 culturc~ 
THP-1 cells. derived from a human monocytlc cell line [16], were 
a kmd gift from Dr J M. Dayer: they were grown m RPM1 1640 
medium (Flow, McLean. VA, USA) supplemented with 10% fetal calf 
serum (Glbco, Gaithesburg. MD. USA). 
2.2. Rrugents 
Human UPA (M, = 55.000) and uPA were obtamed from Serono 
(Denens, Switzerland). human plasmmogen from Sigma (St. Louis. 
MO. USA) and recombmant human PAI- from Behring (Marburg, 
Germany). 
2.3. Iodnution oj uPA 
uPA was radlolabelled as described [17], by lodogen (Pierce Chem- 
ical Co.. Rockford. IL. USA) and Na-“iI (Amersham Internatlonal. 
Amersham. UK) 
2.4. SDS-PAGE untl uutwwhogruph, 
Samples were electrophoresed in the presence of sodium dodecylsul- 
fate (SDS). under non-reducmg conditions. in 12% polqacrylamide 
gels, m Laemmli buffer [I 81 and stained with Coomassie brllllant blue 
R250. Gels were dried and exposed to Kodak XAR films (Eastman 
Kodak, Rochester. NY. USA) 
This was performed as described [17]. by layermg the SDS-12% 
polyacrylamide gels over a 0 8% agarose resolvmg gel contammg 2% 
non-fat dry milk (Blo-Rad, Richmond, CA. USA) as a source of casein 
and 0.4 mg/ml of purified human plasmmogen m 0.1 M T‘ris-HCI 
buffer, pH 7.5. The plasmmogen-dependent caaeinolysis appeared as 
a clear band of lysis on the opaque background 
For bmding assays. 5 x lo-’ M [“I]uPA was incubated with 
2 x IO-’ M PA1-3 for 1 h. at 4’C m RPM1 medium additioned with 
bovine serum albumm (BSA) (I mg/ml) The formation of the com- 
plexes was ascertamed by SDS-PAGE and autoradiography 
Cells were collected, washed three times in phosphate-buffered ra- 
line (PBS). BSA (I mg/ml) was added and stripped of surface-bound 
endogenous uPA by acid treatment as described elsewhere [12]. 
Briefly. cells were incubated for 3 min at 4°C m 50 mM glycme, 100 
mM NaCl. pH 3.0. half a volume of 50 mM HEPES, 100 mM NaCl. 
pH 7.4. was then added for neutralization. After 3 washes m RPMI- 
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BSA. cells were Incubated. If not otherwlse Indicated, for 2 h at 4°C. 
with “51-labelled UPA alone (5 x IO-’ M) or ulth preformed [“51]uPAm 
PAI- complexes. After mcubatlon, cells were washed three times with 
PBSBSA and the surface-bound radloactlvity was measured Cells 
were then treated with acid or neutral buffer. 
Cell density at each step was 2 x 10h/lOO~l ofmedium. To inactIvate 
latent proteases. BSA solutions were acidified by adding HCI to pH 
3.0. stirred 2 h at room temperature and then neutralized with NaOH 
to pH 7.2. 
After bmdmg with uPA or uPA_PAI- complexes, cells were 
mashed and Incubated with or without 1 mM disuccimmldyl suberate 
(DSS) for 15 mm at room temperature. The reactlon was stopped by 
adding l/IO (v/v) of 100 mM ammonium acetate After 10 min. cells 
were washed. lysed and analyzed by SDS-PAGE and autorddiogra- 
phy. 
After bindmg with uPA_PAI- complexes. 50~1 of acid eluates were 
incubated for 2 h at 4°C with 1 lug of an antI-ATF monoclonal 
antibody (Blopool. Umea. Sweden) or with 1 ~1 of normal mouse 
serum. Then protein A-Sepharose (Pharmacla. Uppsala. Sweden) was 
added. v/v. for 30 mm at room temperature. The resin had been 
previously washed with 0.5% Nomdet P-40 m 0.5 M NaCl, 1 mM 
EDTA, 50 mM Trls-HCl. pH 8.1 (NET buffer) and diluted to 10% m 
NET buffer contaming 0 05% Nomdet P-40. The Immunopreclpitate 
was sequentially washed m NET buffer supplemented with 1% Trlton 
X-100 and 0.2% SDS. NET buffer contaming 1% SDS supplemented 
with 60 mg/ml urea and in 0.5 M NaCI. 50 mM Trls-HCI. pH 8.1,0.1% 
SDS. Finally the lmmunocomplexes nere eluted by bodmg the samples 
for IO min m Laemmh buffer. and analyzed by SDS-PAGE and 
autoradlography 
3. RESULTS 
All the following experiments were performed with 
THP-1 cells that express a uPA receptor that has the 
same characteristics as the UPA receptor of another 
monocyte-like cell line, U937. In contrast to the latter, 
however. THP-1 cells do not produce high levels of 
PAIs [13]. 
To investigate the interaction between UPA, PAI- 
and their cellular binding sites. THP-1 cells, stripped of 
endogenous uPA by acid treatment, were incubated for 
2 h at 4°C with preformed UPA-PAI- complexes or 
with UPA alone. Binding of complexes could also be 
achieved by sequential incubation of acid-treated cells 
with uPA, for 2 h at 4”C, and then with PAI- 1 h at 
4°C. without changing the final result. After the incuba- 
tion with the ligands. cells were treated with acid. to 
elute all bound material from the surface, and the elu- 
ates were analyzed by SDS-PAGE under non-reducing 
conditions. 
The electrophoretic analysis of the commercial UPA 
used throughout the experiments. showed that it was a 
mixture of .55- and 33-kDa molecules (Fig. 1. lane 3). 
Accordingly, preformed uPA-PAI- complexes pre- 
sented two bands of 92 and 73 kDa apparent molecular 
mass (Fig. 1, lane 1). In order to saturate the enzyme 
with the inhibitor [12.13] we used a fourfold excess of 
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PAI- with respect to UPA. Under these conditions, 
however. the electrophoretic analysis showed that a 
small fraction of the enzyme was still free. 
The SDS-PAGE analysis of the acid eluates showed 
two bands corresponding to the molecular weights of 
uPAPAI- complexes and free UPA (92 and 55 kDa, 
respectively), and two additional major bands at 70 and 
22 kDa. which were apparently, degradation products 
of the 92-kDa complex (Fig. 1, lane 3). The same result 
was obtained with lysates of cells not treated with acid 
(not shown). As expected, there were no bands of 33 and 
73 kDa since uPA does not bind to the cell surface. 
In the absence of PAI-2, the only major band observed 
was of 55 kDa, corresponding to free UPA (Fig. 1. lane 
5). 
3.2. Analysis of the degrudation products of uPA_PAI- 
complexes bound to THP-I cells 
To identify the components of the bands observed in 
the presenct of PAI- (92, 70. 55 and 22 kDa), the same 
samples previously analyzed by SDS-PAGE were ana- 
lyzed by zymography and immunoprecipitation with 
specific antibody. 
The zymographic analysis (Fig. 2) showed that a 
caseinolytic activity. indicating the presence of the B 
chain, was associated only with the bands of 92, 70 and 
1 2 34 56 
kD 
22 + 
N 
2 d 
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d = Acid + - + - 
d 3 
Fig. 1. Binding of [‘“‘I]uPA-PAI- complexes to THP-1 cells. THP-1 
cells were incubated with [‘2sI]uPA-PAI-2 complexes (lanes 3 and 4) 
or with uPA alone (lanes 5 and 6) then treated with acid (lanes 3 and 
5) or with neutral buffer (lanes 4 and 6). Preformed uPA_PAI- com- 
plexes (lane l), UPA (lane 2) and eluates (lanes 3-6) were analyzed by 
SDS-12% PAGE and autoradiography. In thts figure and in the fol- 
lowing ones. the molecular weights were estimated from the migration 
of standards. 
1 2 
kD 
92- / 
70- /f 
55- + 
\,~ 
i 
22- 
Fig. 2. Zymographic analysis of uPA-PAI- complexes and their deg- 
radation products bound on THP-1 cells After incubation with UPA- 
PAI- complexes THP-1 cells were treated with acid. The eluate was 
analyzed in duplicate by SDS-12% PAGE followed by zymography of 
intact gel (panel 1) and strips correspondmg to different molecular 
wetghts (panel 2) 
55 kDa: there was no enzymatic activity in association 
with the 22-kDa band, which probably represented the 
A chain or a part of it (panel 1). The two bands of 92 
and 70 kDa were very weak. probably due to the pres- 
ence of the inhibitor [ 191 and merged into a smear, when 
the incubation was prolonged: therefore we cut the gel 
in strips corresponding to different molecular weights 
and incubated them separately for the time required to 
give distinct bands (panel 2). 
Immunoprecipitation with a monoclonal antibody 
against the ATF yielded only the three bands of 92. 55 
and 22 kDa (Fig. 3. lane 3). Therefore the 70-kDa deg- 
radation product did not contain the ATF region of 
UPA. Finally, analysis by lo-20% SDS-PAGE under 
reducing conditions showed that the 22 kDa fragment 
co-migrated with the A chain of UPA (not shown). 
3.3. Effects of the degradation process on the uPA recep- 
tor 
THP-1 cells. after binding with UPA or uPA_PAI- 
complexes, were acid-stripped. incubated again with la- 
belled UPA for 2 h at 4”C, lysed and analyzed by SDS- 
PAGE. The results showed that preincubation with 
complexes or UPA alone did not affect the capacity of 
THP-1 cells to bind newly added UPA (Fig. 4, lanes 4 
and 6) as compared to control THP-1 cells that had not 
been preincubated (lane 2). Moreover, if the cells were 
treated with DSS before the SDS-PAGE analysis, there 
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1 
kD 
2 3 4. DISCUSSION 
In this study of the interaction between the UPA-PAI- 
2 complex and the UPA receptor we provide evidence of 
a new cellular binding site for the degraded complex. 
We first performed the binding between THP-1 cells, 
which express a uPA receptor, and the uPA-PAI- com- 
plex at 4”C, to block endocytosis, and then we analyzed 
by SDS-PAGE the radioactive products bound to the 
cells. Unexpectedly, in addition to the bands corre- 
sponding to UPA (55 kDa), the native uPA55-PAI- 
complex (92 kDa), and the previously reported 70-kDa 
degradation product of the native complex [ 131, we ob- 
served a 22-kDa band not previously described (Fig. 1, 
lane 3). All the bands were acid-elutable, and therefore 
they were exposed on the cellular surface. The first im- 
portant consequence of this observation is that the deg- 
radation process of the uPA_PAI- complex, already 
described in THP- 1 cells [ 131, does not involve, as sug- 
gested. the PAI- molecule, but rather UPA itself. The 
complexed enzyme, in fact. is cleaved into two pieces: 
the 22-kDa fragment and another fragment, which is 
part of the 70-kDa degradation product. The sum of the 
mAb a-ATF - +. 
Acid 
eluates 
Fig. 3. Immunoprecipitation of [‘251]uPA-PAI-2 complexes and their 
degradation products bound to THP-1 cells. After the binding of 
[“51]uPA-PAI-2 to THP-1 cells, acid eluates were incubated with an 
anti-ATF mouse monoclonal antibodies (lane 3) or a nommmune 
mouse serum (lane 2). The immunocomplexes were precipitated by 
protein A-Sepharose. eluted m Laemmli buffer and analyzed by SDS- 
12% PAGE and autoradiography. Lane 1. acid eluate from THP-I 
cells incubated wtth [“‘I]uPA~PAI-2 complexes before the im- 
munoprecipitation. 
was no shift of the 100 kDa band representing uPA 
bound to uPAR (lanes 3 and 5) as compared to control 
cells (lane 1). These two observations suggest that the 
degradation process does not affect the functioning of 
the receptor and that the products of this process (70 
and 22 kDa) do not contain significant amounts of 
uPAR or fragments of it. 
THP-1 cells preincubated with uPA--PAI- com- 
plexes, not acid-stripped and incubated again with la- 
belled uPA, did not bind the newly added enzyme (not 
shown). thus indicating that all uPA receptors were oc- 
cupied even after degradation of the complex. More- 
over, the 22-kDa fragment could still be eluted by acid 
treatment, even after 150 min at 37°C (Fig. 5, lane 2). 
It is interesting to note that after 150 min at 37°C. all 
bound 92-kDa uPA-PAI- complexes had been proc- 
essed and that also the 70-kDa species had disappeared, 
probably following endocytosis or release into the me- 
dium. In the absence of PAI- (Fig. 5, lanes 3 and 4), 
UPA remained intact, even after 150 min. 
123456 
kD 
100 + 
-, * 6’ 
--- 
PREBINDING NONE uPAs “PAS 
PAI- 
DSS +- +- +- 
Fig. 4. Effect of the degradation process of uPA-PAI- complexes on 
the uPA receptor. THP-I cells, after incubation with [““I]uPA-PAI- 
complexes (lanes 5 and 6). [“‘I]uPA alone (lanes 3 and 4) or medium 
(lanes 1 and 2) were actd-treated and re-incubated with fresh 
[“51]uPA. Fmally. cells were treated with DSS (lanes 1. 3 and 5) or 
without (lanes 2.4 and 6). lysed and analyzed by SDS-12% PAGE and 
autoradiography. 
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37°C 30' 150' 30' 150' 
Fig. 5. Fate of UPA-PAI- complexes bound to THP-1 cells, at 37°C. 
THP-I cells were incubated at 37°C with [“51]uPA-PAI-2 complexes 
(lanes 1 and 2) or [“51]uPA alone (lanes 3 and 4), for the indicated 
times. Cells were then washed, treated with acid and the eluates were 
analyzed by SDS-12% PAGE and autoradiography. 
molecular masses of the two molecules equals the mo- 
lecular mass of the native complex (92 kDa). The cleav- 
age of UPA takes place only when the enzyme is com- 
plexed to its inhibitor. The 22-kDa band has probably 
eluded detection because in the generally used 10% 
SDS-PAGE it migrates with the front. Immunoprecipi- 
tation with monoclonal anti-ATF antibodies and zy- 
mography proved that the 70-kDa degradation product 
contained the active site of the enzyme. i.e. the B chain, 
while the 22-kDa molecule consisted of the A chain, 
which is devoid of activity (Figs. 2 and 3). 
The cleavage of the bound complex does not involve 
the UPA receptor, because, after acid elution of native 
complexes and of their degradation products, cells 
bound fresh labelled UPA to the same extent as control 
cells (Fig. 4). We cannot exclude some degradation of 
the PAI- molecule, although no major degradation 
products were observed. 
Whereas the 22-kDa molecule most probably binds 
to the cellular surface by the canonic receptor, the 70- 
kDa molecule could not, because it lacks the ATF. This 
suggested the existence of a different receptor for the 
larger fragment or of a novel subunit (or binding site) 
of the canonic UPA receptor, which could bind the B 
chain of UPA or PAI- or both. However, uPA333PAI- 
2 complexes do not bind THP-1 cells ([ 131 and our 
unpublished observation), thus suggesting that the sec- 
ond site is not available on the cell surface, unless the 
native UPA-PAI- complex is bound by the canonic site 
for ATF. 
The specificity of the second binding site remains to 
be established. We performed competition experiments 
(not shown) between preformed, labelled uPA_PAI- 
complexes and cold competitors, such as uPA, PAI-2, 
uPA33, UPA-PAI- and uPAPAI- complexes. The 
results were not conclusive and although they suggested 
a low affinity of the novel site for PAI-2, since PAI- 
alone and uPA333PAI-2 complexes weakly inhibited 
(20- 30%) the binding of intact UPA-PAI- complexes, 
we cannot exclude that the second binding involves also, 
or only, uPA. Experiments with phospholipase C 
(PLC), which cleaves the GPI anchor of the UPA recep- 
tor, might be relevant in this regard; if the receptor is 
occupied by the UPA-PAI- complex and not by UPA 
alone. it is somehow protected from the PLC action, 
probably because of a physical contact between the re- 
ceptor and the inhibitor [20]. 
Cross-linking experiments performed with DSS on 
THP-1 cells incubated with uPA_PAI- complexes did 
not provide useful information: no new and unexpected 
band. that could not be accounted for by adding the 
molecular weight of the enzyme, the inhibitor and the 
receptor, was observed (not shown). On the basis of this 
observation, we cannot exclude the presence of a differ- 
ent receptor, i.e. the low density lipoprotein receptor 
related protein (LRP)R macroglobulin receptor (2MR) 
[21], or of a different subunit of uPAR, which could 
have been inaccessible or not amenable to cross-linking 
by DSS. 
In conclusion. there are several steps that precede the 
endocytosis of the uPA-PAI- complex. These steps can 
be examined by blocking the whole process at 4”C, just 
before endocytosis. On the basis of our observations, we 
propose the following model of the interaction between 
uPA, PAI- and uPAR: 
(1) The UPA-PAI- complex binds with high affinity to 
the canonic receptor via the ATF region. The binding 
could determine a conformational modification of the 
receptor, thus exposing a new binding site, possibly for 
PAI-2; alternatively, it could somehow allow the bind- 
ing of the complex to a different receptor, as described 
for the uPA_PAI-I complex [31]. 
(2) These two almost contemporaneous bindings could 
stretch the complex, causing it to cleave in two frag- 
ments of 70 and 22 kDa bound, respectively, to the 
novel binding site and the binding site for ATF. 
(3) At 37°C the 70-kDa species is endocytosed or re- 
leased; the 22-kDa fragment would remain outside the 
cell, on its own binding site, since it is still acid-elutable 
after 150 min at 37°C. Therefore, the final result of this 
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process is that the concentrated proteolytic activity lo- 
calized on the cell membrane is completely neutralized; 
in fact, the B chain is first inhibited by PAI- and then 
endocytosed or released, while the A chain. catalytically 
inactive, continues to occupy the UPA receptor on the 
cell membrane. thus preventing the binding of new ac- 
tive uPA. 
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